Global pharmaceutical leader Boehringer Ingelheim has announced its acquisition of Evax AG, a Swiss biotechnology firm specializing in advanced therapeutic vaccines for horses. This strategic move aims to pioneer new treatments for allergic skin diseases, a significant and challenging health issue in the equine world. The acquisition underscores a commitment to leveraging cutting-edge science to address unmet needs in veterinary medicine.
Addressing a Critical Need in Equine Health
Allergic and dermatological conditions are common afflictions for horses, profoundly affecting their health and overall well-being. Current management options, such as topical treatments and shampoos, often provide only temporary relief and require frequent application. Furthermore, some conventional therapies like corticosteroids can carry significant safety concerns, creating a demand for more sustainable solutions.
Evax AG, founded over a decade ago at the University of Zurich, has been developing a novel solution to this problem. The company's approach utilizes therapeutic vaccines built on virus-like particle technology to target the underlying cause of the disease. These vaccines are designed to prompt the horse’s immune system to produce its own neutralizing antibodies against allergens.
A Strategic Move to Advance Innovation
This acquisition aligns perfectly with Boehringer Ingelheim's strategy to foster breakthrough innovations within its animal health portfolio. The company has a long-standing interest in therapeutic vaccines, which was previously demonstrated by its collaboration with and subsequent 2024 acquisition of Saiba Animal Health. This latest purchase of Evax further solidifies its position in the field of veterinary immunology and targeted therapies.
Knut Elbers, Head of Global Innovation for Animal Health at Boehringer Ingelheim, highlighted the transformative potential of this technology. He noted that virus-like particles represent a truly innovative approach with applications for various high-need areas in animal health. The company believes this platform can play a crucial role in managing chronic diseases in pets and allergy-related disorders in horses.
Leadership Perspectives and Future Outlook
From a practical standpoint, the development promises significant benefits for horse owners and veterinarians. Saskia Kley, Global Head of Equine for Boehringer Ingelheim, expressed excitement about offering the first therapeutic option that targets the disease's root cause. This could lead to longer-lasting effects, superior treatment outcomes, and greater convenience in managing equine allergies.
Dr. Antonia Gabriel, CEO and Founder of Evax, shared her enthusiasm for joining the global animal health leader. She emphasized the opportunity to tap into Boehringer Ingelheim's extensive innovation, supply, and commercial expertise. This collaboration is expected to accelerate the advancement of these novel therapeutic options through the final phases of development and into the market.
The acquisition of Evax AG by Boehringer Ingelheim marks a significant step forward in the treatment of chronic equine conditions. By integrating Evax's pioneering virus-like particle technology, the company is poised to deliver a new class of therapies that are safer and more effective. While financial terms were not disclosed, the deal signals a strong investment in the future of animal well-being and innovation.